[{"NetIncomeLoss_1_Q2_USD":92700000.0,"LongTermDebtCurrent_0_Q2_USD":29100000.0,"LongTermDebt_0_Q2_USD":796900000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1_Q2_shares":900000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2_Q2_shares":900000.0,"OperatingLeaseExpense_1_Q2_USD":300000.0,"OperatingLeaseExpense_2_Q2_USD":600000.0,"AssetsCurrent_0_Q2_USD":795900000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-1100000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-69300000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1_Q2_USD":3400000.0,"IncomeTaxesPaid_2_Q2_USD":12200000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-22200000.0,"OperatingCostsAndExpenses_1_Q2_USD":268700000.0,"OperatingCostsAndExpenses_2_Q2_USD":472800000.0,"InterestPaidNet_2_Q2_USD":11600000.0,"BilledContractReceivables_0_Q2_USD":202200000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2_Q2_USD":6600000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q2_USD":1000000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":145700000.0,"PaymentsForPreviousAcquisition_2_Q2_USD":10000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"OperatingLeaseRightOfUseAsset_0_Q2_USD":24500000.0,"ShareBasedCompensation_2_Q2_USD":31000000.0,"Assets_0_Q2_USD":2466100000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":117100000.0,"CommonStockSharesIssued_0_Q2_shares":54100000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":76000000.0,"TreasuryStockValue_0_Q2_USD":39600000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":32300000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":400000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":600000.0,"TreasuryStockShares_0_Q2_shares":1200000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":129800000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":206700000.0,"ContractWithCustomerLiability_0_Q2_USD":118000000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":42400000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_2_Q2_USD":2100000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":37400000.0,"RestrictedCashCurrent_0_Q2_USD":200000.0,"ProceedsFromLinesOfCredit_2_Q2_USD":0.0,"RepaymentsOfLinesOfCredit_2_Q2_USD":20000000.0,"CommonStockValue_0_Q2_USD":100000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":28000000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":19200000.0,"AccountsReceivableNetCurrent_0_Q2_USD":258600000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":1100000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":56800000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":0.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":53500000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":53200000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-100000.0,"EarningsPerShareBasic_1_Q2_USD":1.76,"EarningsPerShareBasic_2_Q2_USD":1.53,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":138900000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":47900000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":25000000.0,"RevenueRemainingPerformanceObligation_0_Q2_USD":1400000000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.26,"IncreaseDecreaseInEmployeeRelatedLiabilities_2_Q2_USD":-3400000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":33800000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_2_Q2_USD":0.0,"MoneyMarketFundsAtCarryingValue_0_Q2_USD":178700000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"OperatingLeaseLiability_0_Q2_USD":26100000.0,"Liabilities_0_Q2_USD":1267300000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":268800000.0,"OtherAssetsNoncurrent_0_Q2_USD":101600000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":29800000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":15000000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-14500000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":91700000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":67900000.0,"IncreaseDecreaseInInventories_2_Q2_USD":13700000.0,"PaymentForContingentConsiderationLiabilityFinancingActivities_2_Q2_USD":1100000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-15300000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":16900000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":587200000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":394700000.0,"AccountsPayableCurrent_0_Q2_USD":84800000.0,"RepaymentsOfMediumTermNotes_2_Q2_USD":5600000.0,"LiabilitiesCurrent_0_Q2_USD":293700000.0,"BusinessCombinationContingentConsiderationLiabilityCurrent_0_Q2_USD":22300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":52300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":52600000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":185700000.0,"NonoperatingIncomeExpense_2_Q2_USD":-15000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-300000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":11700000.0,"InventoryRawMaterialsAndSuppliesNetOfReserves_0_Q2_USD":81700000.0,"Goodwill_0_Q2_USD":266300000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-1000000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-12300000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":234400000.0,"AmortizationOfFinancingCosts_2_Q2_USD":1500000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-400000.0,"NonoperatingIncomeExpense_1_Q2_USD":-5300000.0,"InterestExpense_2_Q2_USD":15000000.0,"InterestExpense_1_Q2_USD":6400000.0,"NetIncomeLoss_2_Q2_USD":80200000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":580100000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":6900000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1_Q2_USD":800000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2_Q2_USD":3600000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":16800000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":63900000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":693200000.0,"AdditionalPaidInCapital_0_Q2_USD":758500000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.042,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":693200000.0,"LongTermDebtNoncurrent_0_Q2_USD":758100000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":23100000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":32100000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":269000000.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":27200000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":90600000.0,"EarningsPerShareDiluted_2_Q2_USD":1.51,"CommonStockSharesOutstanding_0_Q2_shares":52900000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":2466100000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":-3700000.0,"PreferredStockValue_0_Q2_USD":0.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":822100000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":32700000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2_Q2_USD":1100000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q2_USD":29200000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":59000000.0,"InventoryNet_0_Q2_USD":236200000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2_Q2_USD":-11900000.0,"NotesPayableCurrent_0_Q2_USD":29100000.0,"AllowanceForDoubtfulAccountsReceivable_0_Q2_USD":500000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":120700000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":99400000.0,"OperatingIncomeLoss_1_Q2_USD":126000000.0,"OperatingIncomeLoss_2_Q2_USD":114400000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1_Q2_USD":-700000.0,"PreferredStockSharesAuthorized_0_Q2_shares":15000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":31000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":24400000.0,"DeferredTaxAssetsGross_0_Q2_USD":22300000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-12100000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":101000000.0,"LeaseCost_1_Q2_USD":1300000.0,"LeaseCost_2_Q2_USD":2700000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":502000000.0,"DeferredCostsCurrent_0_Q2_USD":40600000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":59300000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":85300000.0,"StockholdersEquity_0_Q2_USD":1198800000.0,"OtherLiabilitiesCurrent_0_Q2_USD":32000000.0,"FinitelivedIntangibleAssetsAcquired1_2_Q2_USD":10000000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":59400000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":21600000.0,"UnbilledContractsReceivable_0_Q2_USD":56400000.0,"DeferredFinanceCostsNoncurrentNet_0_Q2_USD":9700000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":814500000.0,"EarningsPerShareDiluted_1_Q2_USD":1.73,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":29100000.0,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20200731"}]